Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EN05.
Mechanism of action
Veraxanib is a selective, potent, reversible inhibitor of fibroblast growth factor receptor 2 (FGFR2) kinase. It inhibits FGFR2 autophosphorylation and downstream signalling through the MAPK and PI3K/AKT pathways in tumour cells harbouring FGFR2 gene fusions or activating mutations, leading to inhibition of cell proliferation and induction of apoptosis.
Clinical efficacy
Efficacy was established in study VRXB-101, an open-label, single-arm trial in 112 patients with advanced FGFR2-altered solid tumours who had received at least one prior line of systemic therapy. The primary endpoint was overall response rate (ORR) by independent radiological review.
The ORR was 38% (95% CI: 29–47%), with a median duration of response of 9.3 months (95% CI: 7.2–12.1 months). Median progression-free survival was 7.1 months (95% CI: 5.8–8.6 months). Median overall survival was not yet reached at the time of analysis.
Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EN05 (provisional).
Mechanism of action
Veraxanib is a selective, potent, reversible inhibitor of fibroblast growth factor receptor 2 (FGFR2) kinase. It inhibits FGFR2 autophosphorylation and downstream signalling through the MAPK and PI3K/AKT pathways in tumour cells harbouring FGFR2 gene fusions or activating mutations, leading to inhibition of cell proliferation and induction of apoptosis.
Clinical efficacy
Efficacy was established in study VRXB-101, an open-label, single-arm trial in 112 patients with advanced FGFR2-altered solid tumours who had received at least one prior line of systemic therapy. The primary endpoint was overall response rate (ORR) by independent radiological review.
The ORR was 38% (95% CI: 29–47%), with a median duration of response of 9.3 months (95% CI: 7.2–12.1 months). Median progression-free survival was 7.1 months (95% CI: 5.8–8.6 months).
Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EN05 (provisional).
Mechanism of action
Veraxanib is a selective, potent, reversible inhibitor of fibroblast growth factor receptor 2 (FGFR2) kinase. It inhibits FGFR2 autophosphorylation and downstream signalling through the MAPK and PI3K/AKT pathways in tumour cells harbouring FGFR2 gene fusions or activating mutations.
Clinical efficacy
Efficacy was established in study VRXB-101, an open-label, single-arm trial in patients with advanced FGFR2-altered solid tumours. The primary endpoint was overall response rate (ORR) by independent radiological review.